• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Vaccines as an Integral Component of Cancer Immunotherapy.疫苗作为癌症免疫治疗的一个组成部分。
JAMA. 2018 Dec 4;320(21):2195-2196. doi: 10.1001/jama.2018.9511.
2
Immunotherapy: Cancer vaccines on the move.免疫疗法：不断发展的癌症疫苗。
Nat Rev Clin Oncol. 2018 Jan;15(1):9-10. doi: 10.1038/nrclinonc.2017.149. Epub 2017 Sep 12.
3
New perspectives in cancer immunotherapy and immunomonitoring.癌症免疫治疗与免疫监测的新视角
Future Oncol. 2009 Sep;5(7):941-4. doi: 10.2217/fon.09.62.
4
Cancer vaccines and immunotherapy.癌症疫苗与免疫疗法。
Hum Vaccin. 2009 Oct;5(10):666. doi: 10.4161/hv.5.10.9132. Epub 2009 Oct 1.
5
Vaccines targeting tumor vasculature: a new approach for cancer immunotherapy.靶向肿瘤血管的疫苗：癌症免疫治疗的新方法。
Cytotherapy. 2007;9(1):1-3. doi: 10.1080/14653240601118444.
6
Therapeutic cancer vaccines.治疗性癌症疫苗
Vaccine. 2007 Sep 27;25 Suppl 2:B1-3. doi: 10.1016/j.vaccine.2007.06.042. Epub 2007 Aug 2.
7
Personalized Cancer Vaccines Advance in the Clinic.个性化癌症疫苗在临床中取得进展。
J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx245.
8
The Dawn of a New Age in Cancer Immunotherapy.癌症免疫疗法新时代的曙光
Surg Oncol Clin N Am. 2019 Jul;28(3):xv-xvi. doi: 10.1016/j.soc.2019.04.002. Epub 2019 Apr 20.
9
Vaccine immunotherapy for cancer.癌症的疫苗免疫疗法。
Mol Cell Biol Hum Dis Ser. 1995;5:140-56. doi: 10.1007/978-94-011-0547-7_8.
10
Immunotherapy for Solid Malignancies.实体恶性肿瘤的免疫疗法。
Surg Oncol Clin N Am. 2019 Jul;28(3):xiii-xiv. doi: 10.1016/j.soc.2019.04.001. Epub 2019 Apr 20.

引用本文的文献

1
Combined cancer immunotherapy with lipid nanoparticle delivery of oligo-based cGAS-agonistic adjuvant and peptide or mRNA vaccines.联合癌症免疫疗法，采用基于寡核苷酸的cGAS激动剂佐剂以及肽或mRNA疫苗的脂质纳米颗粒递送。
Mol Ther Nucleic Acids. 2025 Jul 1;36(3):102623. doi: 10.1016/j.omtn.2025.102623. eCollection 2025 Sep 9.
2
Intranodal injection of neoantigen-bearing engineered triggers epitope spreading and systemic tumor regressions.携带新抗原的工程化物质的结内注射引发表位扩展和全身性肿瘤消退。
Acta Pharm Sin B. 2025 Apr;15(4):2217-2236. doi: 10.1016/j.apsb.2025.02.041. Epub 2025 Mar 8.
3
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer.TEDOVA：在铂类敏感复发性卵巢癌中，OSE2101 疫苗 +/- 帕博利珠单抗作为维持治疗。
Future Oncol. 2024;20(35):2699-2708. doi: 10.1080/14796694.2024.2386922. Epub 2024 Aug 19.
4
Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines.自体树突状细胞负载来自自我更新的自体肿瘤细胞的抗原，作为患者特异性治疗性肿瘤疫苗。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2198467. doi: 10.1080/21645515.2023.2198467. Epub 2023 May 3.
5
Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy.用于联合肿瘤免疫治疗中双佐剂和新抗原共递送的可电离聚合物纳米载体。
Bioact Mater. 2023 Aug;26:169-180. doi: 10.1016/j.bioactmat.2023.02.016. Epub 2023 Mar 3.
6
Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies.基于多重流式细胞术的检测方法，用于定量分析免疫治疗引起的肿瘤和病毒相关抗体。
Front Immunol. 2022 Nov 16;13:1038340. doi: 10.3389/fimmu.2022.1038340. eCollection 2022.
7
Antitumor Peptide-Based Vaccine in the Limelight.备受瞩目的基于抗肿瘤肽的疫苗。
Vaccines (Basel). 2022 Jan 3;10(1):70. doi: 10.3390/vaccines10010070.
8
A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells.一种治疗性癌症疫苗利用基因修饰的 T 细胞将抗原和佐剂递送到淋巴组织。
J Clin Invest. 2021 Aug 16;131(16). doi: 10.1172/JCI144195.
9
Distinct difference in tumor-infiltrating immune cells between Wilms' tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies.肾母细胞瘤基因1肽疫苗与抗程序性细胞死亡蛋白1抗体疗法在肿瘤浸润免疫细胞方面存在明显差异。
Neurooncol Adv. 2021 Jun 29;3(1):vdab091. doi: 10.1093/noajnl/vdab091. eCollection 2021 Jan-Dec.
10
Immunology of Lynch Syndrome.林奇综合征的免疫学
Curr Oncol Rep. 2021 Jun 14;23(8):96. doi: 10.1007/s11912-021-01085-z.

本文引用的文献

1
Current status and perspectives in immunotherapy for metastatic melanoma.转移性黑色素瘤免疫治疗的现状与展望
Oncotarget. 2018 Jan 3;9(15):12452-12470. doi: 10.18632/oncotarget.23746. eCollection 2018 Feb 23.
2
Estimation of clinical trial success rates and related parameters.临床试验成功率及相关参数的估计。
Biostatistics. 2019 Apr 1;20(2):273-286. doi: 10.1093/biostatistics/kxx069.
3
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.M7824（MSB0011359C）的 I 期临床试验，一种双功能融合蛋白，靶向 PD-L1 和 TGFβ，用于晚期实体瘤。
Clin Cancer Res. 2018 Mar 15;24(6):1287-1295. doi: 10.1158/1078-0432.CCR-17-2653. Epub 2018 Jan 3.
4
Cancer immunotherapies targeting the PD-1 signaling pathway.靶向PD-1信号通路的癌症免疫疗法。
J Biomed Sci. 2017 Apr 4;24(1):26. doi: 10.1186/s12929-017-0329-9.
5
MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human Carcinomas.MUC1-C 癌蛋白在人类癌中整合 EMT、表观遗传重编程和免疫逃逸程序。
Biochim Biophys Acta Rev Cancer. 2017 Aug;1868(1):117-122. doi: 10.1016/j.bbcan.2017.03.003. Epub 2017 Mar 14.
6
Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.先天免疫的替代体外激活与白细胞介素-7协同作用，促使天然识别MUC1、HER2/neu和其他肿瘤相关抗原的CD4+和CD8+人外周血T细胞在抗原驱动下快速增殖。
Oncotarget. 2017 Feb 14;8(7):10785-10808. doi: 10.18632/oncotarget.13911.
7
Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.靶向转录因子 Brachyury 的酵母基治疗性癌症疫苗（GI-6301）的 I 期临床试验。
Cancer Immunol Res. 2015 Nov;3(11):1248-56. doi: 10.1158/2326-6066.CIR-15-0119. Epub 2015 Jun 30.
8
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.替莫唑胺胶丸联合放疗治疗恶性脑胶质瘤的疗效观察
J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26.
9
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.新型抗 PD-L1 抗体avelumab（MSB0010718C）在人肿瘤细胞上的抗体依赖细胞细胞毒性活性。
Cancer Immunol Res. 2015 Oct;3(10):1148-1157. doi: 10.1158/2326-6066.CIR-15-0059. Epub 2015 May 26.
10
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.在转移性、无症状激素难治性前列腺癌患者中进行的西妥昔单抗-T（APC8015）免疫治疗的安慰剂对照III期试验。
J Clin Oncol. 2006 Jul 1;24(19):3089-94. doi: 10.1200/JCO.2005.04.5252.

Vaccines as an Integral Component of Cancer Immunotherapy.

作者信息

Schlom Jeffrey, Gulley James L

机构信息

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

出版信息

JAMA. 2018 Dec 4;320(21):2195-2196. doi: 10.1001/jama.2018.9511.

DOI:10.1001/jama.2018.9511
PMID:30419097
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6538063/
Abstract
摘要